|By PR Newswire||
|February 11, 2013 09:39 AM EST||
HIGH WYCOMBE, England, February 11, 2013 /PRNewswire/ --
- Today, the SMC announced that Rienso has been accepted for restricted use within NHS Scotland for the treatment of iron deficiency anaemia (IDA) in non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used
- The clinical efficacy and safety of Rienso has been assessed in over 1,500 subjects from its clinical development programme, and supported by observational data in more than 8,600 patients and 33,000 doses administered in clinical practice1-3
- Rienso offers a convenient and cost-competitive alternative for delivering a repletion course of IV iron, and requires fewer bolus injections over a shorter period of time when compared to most other IV iron preparations1,4-8
- Takeda looks forward to making Rienso available to patients in Scotland as part of its ongoing commitment to improving management of IDA
Today, Takeda UK announces the Scottish Medicines Consortium's (SMC) acceptance of Rienso (ferumoxytol), a new intravenous (IV) iron therapy to treat iron deficiency anaemia (IDA) restricted to non-haemodialysis dependent adult patients with chronic kidney disease (CKD) when oral iron preparations are ineffective or cannot be used. All eligible patients in NHS Scotland will now be able to receive Rienso, offering a convenient and cost-effective alternative to current IV iron therapies.1,4-8
"Rienso will be a valuable addition to the currently available therapies for IDA as an effective and convenient method for delivering high dose iron; a significant consideration for non-dialysis patients who maintain an independent lifestyle. Its acceptance by the SMC will be of real benefit to the Scottish renal community." - Professor Alan Jardine, University of Glasgow.
Anaemia continues to place a significant burden on the daily lives of CKD patients, despite the availability of treatments to address the condition.9 Effective and efficient delivery of high doses of IV iron can lead to less disruption to the daily life of CKD patients, brought about by less time spent away from their home, family and work.8 Additionally, fewer patient visits can help improve the efficiency of service delivery leading to cost savings for the NHS.8
Marketing authorisation for Rienso was granted by the European Commission on 15 June 2012.1 Administered as a rapid IV injection, Rienso can be given to most adults as two x 510 mg doses administered 2-8 days apart, the benefits of which are rapid repletion of iron stores in anaemic CKD patients, with fewer bolus injections when compared to most other IV iron preparations.1,4-8 Rienso also offers the NHS a cost-competitive solution when compared to the alternative high bolus dose IV iron.7
Iron deficiency is a common cause of anaemia often seen in the later stages of CKD, and can have a profound impact on patients' lives, causing fatigue, shortness of breath and an increase in the risk of cardiovascular (CV) complications including congestive heart failure.9 Management of IDA is therefore an important aspect of care for patients with CKD and in Scotland alone, over 11,000 non-haemodialysis dependent CKD patients are estimated to suffer from anaemia.10
"Takeda are committed to improving the lives of patients worldwide, particularly in CKD, a profoundly debilitating condition for the patients who suffer from it. Acceptance of Rienso by the SMC marks an important milestone in providing physicians with a valuable alternative in the management of CKD patients with IDA in Scotland." - Yasuhiro Fukutomi, Managing Director of Takeda UK.
Rienso has been shown in clinical studies to significantly increase haemoglobin levels, with a similar overall treatment-related adverse event rate as compared to oral iron across the spectrum of CKD; based on data from over 1,500 subjects.1 Compared to the most widely prescribed IV iron preparation, the FIRST (Ferumoxytol Compared to Iron Sucrose Trial) study demonstrated that Rienso, delivered as two injections of 510 mg within 2-8 days, had a similar safety and comparable efficacy profile to 1 g of iron sucrose dosed as 100 mg or 200 mg over 5 to 10 injections within 2-2.5 weeks.11
Moreover, these data are supported by additional retrospective analyses conducted in the United States involving more than 8,600 patients and more than 33,300 administered doses of Rienso.2,3
NOTES FOR EDITORS
Recommendation from the SMC
ADVICE: following a full submission
Ferumoxytol (Rienso®) is accepted for restricted use within NHS Scotland.
Indication under review: Intravenous treatment of iron deficiency anaemia in adult patients with chronic kidney disease.
SMC restriction: treatment of iron deficiency anaemia in non-haemodialysis dependent adult patients with chronic kidney disease when oral iron preparations are ineffective or cannot be used.
In two Phase III studies the mean increase from baseline in haemoglobin was significantly higher for ferumoxytol than oral iron in non-haemodialysis dependent patients with chronic kidney disease. A mixed treatment comparison demonstrated equivalent efficacy outcomes for ferumoxytol versus a range of intravenous iron preparations.
About Rienso® (ferumoxytol)
Ferumoxytol is an IV iron therapy with an approved indication for the treatment of IDA in adult patients with CKD. When patients are iron deficient ferumoxytol can be administered as an initial 510 mg intravenous injection, followed by a second 510 mg intravenous injection 2-8 days later. For patients with Hb ≤10 g/dL, or 10-12 g/dL and > 50 kg in body weight; the recommended course of ferumoxytol is two injections of 510 mg intravenous iron. Ferumoxytol significantly increases Hb levels in CKD patients with IDA, both on dialysis and in patients not on dialysis compared with oral iron. Clinical trials have also highlighted that ferumoxytol is well tolerated.1
Ferumoxytol was developed by AMAG Pharmaceuticals, Inc (AMAG).1 It received marketing approval as Feraheme from the United States Food and Drug Administration on June 30, 2009 and was commercially launched by AMAG in the United States shortly thereafter. Ferumoxytol received marketing approval in Canada in December 2011, in the European Union in June 2012 and in Switzerland in August 2012, where it will be marketed by Takeda as Rienso®.
A Summary of Product Characteristics is available on the website http://www.medicines.org.uk.
Takeda UK Ltd. is based in High Wycombe, Buckinghamshire and is the UK subsidiary of Takeda Pharmaceuticals Company, responsible for sales and marketing of the company's medicines in the UK.
Located in Osaka, Japan, Takeda Pharmaceutical Company is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine.
Further information about Takeda in the UK is available at http://www.takeda.co.uk.
- Rienso Summary of Product Characteristics (SmPC). Available online at: http://www.medicines.org.uk. Accessed January 2013.
- Schiller B, Bhat P, Sharma A, et al. Safety of Feraheme® (Ferumoxytol) in hemodialysis patients at 3 dialysis chains over a 1-year period. J Am Soc Nephrol 2011; 22: 477A-478A. Abstr FR-PO1573.
- Sharma A, Bhat P, Schiller B, et al. Efficacy of Feraheme® (Ferumoxytol) administration on target hemoglobin levels and other iron parameters across 3 dialysis chains. J Am Soc Nephrol 2011; 22: 485A. Abstr FR-PO1603.
- Venofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
- CosmoFer SmPC. Availabe online at: http://www.medicines.org.uk. Accessed January 2013.
- Monofer SmPC. Available online at: http://www.medicines.org.uk. Accessed January 2013.
- Monthly Index of Medical Specialities (MIMS). January 2013.
- Bhandari S. Beyond efficacy and safety - the need for convenient and cost-effective iron therapy in health care. NDT Plus 2011; 4(Suppl 1): i14-i19.
- O'Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectrum 2008; 21: 12-19.
- Scottish Intercollegiate Guidelines Network. Diagnosis and management of chronic kidney disease. 2008. Available online at: http://www.sign.ac.uk. Accessed January 2013.
- Macdougall IC, McLaughlin J, Fortin GS, Li Z, Strauss WE. The FIRST head-to-head comparison study (Ferumoxytol compared to Iron Sucrose Trial) of the safety and efficacy of ferumoxytol compared with iron sucrose for the treatment of iron deficiency anemia in patients with chronic kidney disease. Presented November 2011 at ASN Kidney Week 2011.
20th Cloud Expo, taking place June 6-8, 2017, at the Javits Center in New York City, NY, will feature technical sessions from a rock star conference faculty and the leading industry players in the world. Cloud computing is now being embraced by a majority of enterprises of all sizes. Yesterday's debate about public vs. private has transformed into the reality of hybrid cloud: a recent survey shows that 74% of enterprises have a hybrid cloud strategy.
Dec. 4, 2016 05:30 AM EST Reads: 1,749
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes how...
Dec. 4, 2016 04:45 AM EST Reads: 4,945
WebRTC is the future of browser-to-browser communications, and continues to make inroads into the traditional, difficult, plug-in web communications world. The 6th WebRTC Summit continues our tradition of delivering the latest and greatest presentations within the world of WebRTC. Topics include voice calling, video chat, P2P file sharing, and use cases that have already leveraged the power and convenience of WebRTC.
Dec. 4, 2016 04:30 AM EST Reads: 1,549
Without lifecycle traceability and visibility across the tool chain, stakeholders from Planning-to-Ops have limited insight and answers to who, what, when, why and how across the DevOps lifecycle. This impacts the ability to deliver high quality software at the needed velocity to drive positive business outcomes. In his general session at @DevOpsSummit at 19th Cloud Expo, Phil Hombledal, Solution Architect at CollabNet, discussed how customers are able to achieve a level of transparency that e...
Dec. 4, 2016 04:30 AM EST Reads: 829
Amazon has gradually rolled out parts of its IoT offerings, but these are just the tip of the iceberg. In addition to optimizing their backend AWS offerings, Amazon is laying the ground work to be a major force in IoT - especially in the connected home and office. In his session at @ThingsExpo, Chris Kocher, founder and managing director of Grey Heron, explained how Amazon is extending its reach to become a major force in IoT by building on its dominant cloud IoT platform, its Dash Button strat...
Dec. 4, 2016 04:00 AM EST Reads: 6,221
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
Dec. 4, 2016 04:00 AM EST Reads: 4,942
Internet-of-Things discussions can end up either going down the consumer gadget rabbit hole or focused on the sort of data logging that industrial manufacturers have been doing forever. However, in fact, companies today are already using IoT data both to optimize their operational technology and to improve the experience of customer interactions in novel ways. In his session at @ThingsExpo, Gordon Haff, Red Hat Technology Evangelist, will share examples from a wide range of industries – includin...
Dec. 4, 2016 03:45 AM EST Reads: 1,545
"We build IoT infrastructure products - when you have to integrate different devices, different systems and cloud you have to build an application to do that but we eliminate the need to build an application. Our products can integrate any device, any system, any cloud regardless of protocol," explained Peter Jung, Chief Product Officer at Pulzze Systems, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 4, 2016 02:15 AM EST Reads: 864
When it comes to cloud computing, the ability to turn massive amounts of compute cores on and off on demand sounds attractive to IT staff, who need to manage peaks and valleys in user activity. With cloud bursting, the majority of the data can stay on premises while tapping into compute from public cloud providers, reducing risk and minimizing need to move large files. In his session at 18th Cloud Expo, Scott Jeschonek, Director of Product Management at Avere Systems, discussed the IT and busin...
Dec. 4, 2016 02:00 AM EST Reads: 3,782
Between 2005 and 2020, data volumes will grow by a factor of 300 – enough data to stack CDs from the earth to the moon 162 times. This has come to be known as the ‘big data’ phenomenon. Unfortunately, traditional approaches to handling, storing and analyzing data aren’t adequate at this scale: they’re too costly, slow and physically cumbersome to keep up. Fortunately, in response a new breed of technology has emerged that is cheaper, faster and more scalable. Yet, in meeting these new needs they...
Dec. 4, 2016 12:30 AM EST Reads: 1,783
The cloud promises new levels of agility and cost-savings for Big Data, data warehousing and analytics. But it’s challenging to understand all the options – from IaaS and PaaS to newer services like HaaS (Hadoop as a Service) and BDaaS (Big Data as a Service). In her session at @BigDataExpo at @ThingsExpo, Hannah Smalltree, a director at Cazena, provided an educational overview of emerging “as-a-service” options for Big Data in the cloud. This is critical background for IT and data professionals...
Dec. 3, 2016 11:00 PM EST Reads: 4,158
"Once customers get a year into their IoT deployments, they start to realize that they may have been shortsighted in the ways they built out their deployment and the key thing I see a lot of people looking at is - how can I take equipment data, pull it back in an IoT solution and show it in a dashboard," stated Dave McCarthy, Director of Products at Bsquare Corporation, in this SYS-CON.tv interview at @ThingsExpo, held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA.
Dec. 3, 2016 11:00 PM EST Reads: 961
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
Dec. 3, 2016 09:30 PM EST Reads: 1,613
@DevOpsSummit taking place June 6-8, 2017 at Javits Center, New York City, is co-located with the 20th International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. @DevOpsSummit at Cloud Expo New York Call for Papers is now open.
Dec. 3, 2016 09:30 PM EST Reads: 1,773
The cloud competition for database hosts is fierce. How do you evaluate a cloud provider for your database platform? In his session at 18th Cloud Expo, Chris Presley, a Solutions Architect at Pythian, gave users a checklist of considerations when choosing a provider. Chris Presley is a Solutions Architect at Pythian. He loves order – making him a premier Microsoft SQL Server expert. Not only has he programmed and administered SQL Server, but he has also shared his expertise and passion with b...
Dec. 3, 2016 08:00 PM EST Reads: 3,958